Foundation Medicine, a molecular information company, is dedicated to transforming the way cancer is understood and treated. The company specializes in providing comprehensive genomic profiling to help oncologists make more informed treatment decisions for their patients.
Foundation Medicine’s genomic profiling tests analyze the DNA and RNA of tumor samples to identify genetic alterations that may be driving the growth of cancer cells. These tests provide valuable insights into the unique genomic makeup of each patient’s cancer, allowing for personalized treatment plans.
One of the key tests offered by Foundation Medicine is FoundationOne CDx, an FDA-approved comprehensive genomic profiling test. This test evaluates a patient’s tumor for genomic alterations in more than 300 cancer-related genes, providing information on potential targeted therapies, clinical trial eligibility, and prognosis. By mapping the genetic landscape of a patient’s cancer, FoundationOne CDx helps oncologists match patients with targeted therapies that directly address the genetic drivers of their specific cancer.
In addition to FoundationOne CDx, Foundation Medicine also offers FoundationOne Liquid, a non-invasive blood test that detects circulating tumor DNA in the bloodstream. This test allows for real-time monitoring of a patient’s cancer, assessing treatment response and identifying emerging resistance mutations.
Foundation Medicine has a robust database called FoundationCORE, which houses genomic profiling data from thousands of patients. This database serves as a valuable resource for researchers and clinicians, enabling them to gain insights into the genomic landscape of cancer and develop new targeted therapies.
Overall, Foundation Medicine plays a pivotal role in advancing precision medicine in oncology. By providing comprehensive genomic profiling tests and valuable molecular information, the company empowers oncologists to make more personalized treatment decisions, ultimately leading to improved patient outcomes in the fight against cancer.
Is Foundation One covered by insurance?
Some commercial health plans such as Cigna and many BlueCross BlueShield plans offer coverage for Foundation MedicineFoundation MedicineFoundation Medicine was founded in 2010 with a mission to bring deep molecular information to the point of care for every patient living with advanced cancer. Since then, we’ve brought genomic testing to patients living with cancer globally and helped accelerate breakthroughs in cancer treatment.https://www.foundationmedicine.com › timelineOur History | Foundation Medicine testing services. Medicare covers FoundationOne®CDx, FoundationOne®Liquid CDx, and FoundationOne®Heme for qualifying patients. FoundationOne CDx is also covered by TRICARE for qualifying patients.
Who acquired Foundation Medicine?
Foundation Medicine Inc. (FMI) was founded in 2010 and became an independent affiliate of the Roche GroupRoche GroupRoche ranks among the world’s leading healthcare companies with its expertise in two core businesses – Diagnostics and Pharmaceuticals. Combined with its strength in biotechnology, the company paves the way to the future of healthcare with innovations in areas such as personalised healthcare.https://www.roche.com › about › historyOur History – Roche in 2018 following the complete acquisition of the organisation by Roche.
What is the Foundation One cancer treatment?
FoundationOne®Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based in vitro diagnostic test for cancer patients with solid tumors.
What is Foundation One medicine?
Foundation MedicineFoundation MedicineFoundation Medicine was founded in 2010 with a mission to bring deep molecular information to the point of care for every patient living with advanced cancer. Since then, we’ve brought genomic testing to patients living with cancer globally and helped accelerate breakthroughs in cancer treatment.https://www.foundationmedicine.com › timelineOur History | Foundation Medicine offers different testing options for all cancer types based on your sample type. Your doctor will determine which test is right for you. The FoundationOne®CDx test is a tissue-based genomic test for solid tumors like lung cancer, colorectal cancer, breast cancer, and prostate cancer.
